We have evidence, however, that the simultaneous acquisition of δ with hepatitis B does not cause an appreciable increase in severity in drug abusers with serologically acute hepatitis B. We have examined 212 drug abusers who developed hepatitis during a continuing outbreak of hepatitis B among drug abusers in Dublin 2 and five long term drug abusing carriers of hepatitis B surface antigen (HBsAg) for δ antigenaemia, using enzyme immunoassay after detergent treatment, and for anti-δ, using enzyme immunoassay with serum as the δ antigen source; the specificity of our test has been confirmed on a sample by Dr Rizzetto (table) .
There was no significant difference in the clinical findings between those with or without S antigenaemia, and there has been one fatal case in this group so far. Six of the 212 patients have become HBsAg carriers and four of these have anti-δ; the fatality occurred in one of these 14 months after the acute episode. Additionally, five have been carriers for several years; we have not found S antigen retrospectively in stored sera from these five, but three have anti-δ. It is not known whether these three acquired their δ infections simultaneously with hepatitis B or subsequently.
It appears that in Ireland the acquisition of S and hepatitis B simultaneously is not usually associated with severe hepatitis, and this is similar to the experience in Sweden, where Moestrup et al (8 January, p 87) found only one fulminant case in 37 with acute hepatitis B and δ. The severe δ associated hepatitis reported from Italy seems to have occurred only in patients who were carriers of hepatitis B 
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